All News
Filter News
Found 77 articles
-
Pfizer Did Not Pursue Possible Evidence of Enbrel Helping with Alzheimer's Due to Low Chance of C...
6/5/2019
Recently released documents indicate that Pfizer spent three years reviewing whether the science supported running a trial on Enbrel in Alzheimer’s. -
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio
5/2/2019
19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation
-
Pfizer Reports First-quarter 2019 Results
4/30/2019
First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and 1% Operational Growth From Upjohn
-
Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health
4/30/2019
2019 EPS guidance updated to be in the range of $8.57 to $8.67 on a reported basis and $5.60 to $5.70 on a non-GAAP basis to reflect the disposition of the Elanco Animal Health business.
-
Pfizer and Eli Lilly and Company announced top-line results from a Phase III clinical trial of two doses of tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee.
-
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
4/18/2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
-
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
3/5/2019
Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted Priority Review for its supplemental Biologics License Application for Emgality® injection for the preventive treatment of episodic cluster headache in adults.
-
When your back hurts, your whole body hurts. This morning, Pfizer and Eli Lilly reported positive results from its Phase III back pain treatment tanezumab.
-
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
2/19/2019
Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain.
-
Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
2/6/2019
Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2018.
-
For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.
-
Pfizer and Lilly's New Type of Pain Drug Meets Endpoints in Osteoarthritis Phase III Trial
1/29/2019
Pfizer and Eli Lilly and Co. announced that their tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis (OA) pain in a Phase III trial. -
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
1/29/2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.
-
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS
1/29/2019
Full-Year 2018 Revenues of $53.6 Billion, Reflecting 2% Operational Growth; Fourth-Quarter 2018 Revenues of $14.0 Billion, Reflecting 5% Operational Growth
-
After conducting a routine research-and-development review, Pfizer is easing away from preclinical biosimilar development. The bottom line is the company is ending five preclinical programs in its biosimilar area and cutting 150 positions.
-
Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting
12/19/2018
2019 revenue is expected to be between $25.3 billion and $25.8 billion, representing mid-single-digit growth driven by volume from newer medicines, including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant and Lartruvo, as well as the recent launch of Emgality.
-
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
11/14/2018
Lilly also plans to submit a supplemental Biologics License Application (sBLA) to the FDA for Emgality for the preventive treatment of episodic cluster headache by the end of the year, reflecting its commitment to disabling headache disorders
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
PFIZER REPORTS THIRD-QUARTER 2018 RESULTS
10/30/2018
Third-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth
-
Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.